替罗非班治疗急性缺血性脑卒中患者的临床效果  

Clinical Effect of Tirofiban on Patients with Acute Ischemic Stroke

作　　者：封野芳 FENG Yefang(Department of Neurology,Second People's Hospital of Huludao City,Huludao 125001,China)

机构地区：[1]葫芦岛市第二人民医院神经内科,辽宁葫芦岛125001

出　　处：《中国医药指南》2020年第36期26-28,共3页Guide of China Medicine

摘　　要：目的观察替罗非班治疗急性缺血性脑卒中患者的临床效果。方法随机选取2016年8月至2018年8月我院收治的106例急性缺血性脑卒中患者,随机分为对照组(单独采用常规尿激酶治疗,53例)和联合组(采用常规尿激酶联合替罗非班治疗,53例)。统计分析两组患者的美国国立卫生院卒中量表(NIHSS)评分、Barthel指数量表(BI)评分、改良Rankin量表(m RS)评分、进展性卒中出现率、出血率、远期病死率及不良反应发生情况。结果联合组患者的NIHSS评分、m RS评分、BI评分、进展性卒中出现率、出血率、不良反应发生率均优于对照组(P<0.05)。结论替罗非班治疗急性缺血性脑卒中患者的临床效果较好,有助于改善患者的神经缺损功能和生活质量,降低不良反应发生率。Objective To observe the clinical effect of tirofiban on patients with acute ischemic stroke.Methods A random selection of 106 patients with acute ischemic stroke admitted to our hospital from August 2016 to August 2018 were randomly divided into a control group(using conventional urokinase therapy alone,53 cases)and a combined group(using conventional urokinase combined with tirofiban treatment,53 cases).The NIHSS scores,Barthel indexes,mRS scores and progressive stroke outcomes current rates,hemorrhage rates,long-term mortality rates and occurrences of side effects of the two groups were statistically analyzed.Results The NIHSS score,mRS score,BI score,the incidence of progressive stroke,the bleeding rate,and the incidence of adverse reactions in the combined group were better than those in the control group(P<0.05).Conclusion Tirofiban has a good clinical effect in the treatment of patients with acute ischemic stroke,helps to improve the patients'neurological deficit function and quality of life,and reduces the incidence of adverse reactions.

关 键 词：急性缺血性脑卒中 替罗非班 进展性卒中 神经功能 生活质量 

分 类 号：R743.3[医药卫生—神经病学与精神病学]